alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 73, Number 18 (Monday, January 28, 2008)]
[Notices]
[Page 4884]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-312]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel, AD Clinical Trial.
    Date: February 18, 2008.
    Time: 1 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20814, (Telephone 
Conference Call).
    Contact Person: Ramesh Vemuri, PhD, Scientific Review Office, 
National Institute on Aging, National Institutes of Health, 7201 
Wisconsin Avenue, Suite 2C-212, Bethesda, MD 20892, 301-402-7700, 
<a href="/cdn-cgi/l/email-protection#4f3d397d7c3d0f21262761282039"><span class="__cf_email__" data-cfemail="6d1f1b5f5e1f2d030405430a021b">[email protected]</span></a>.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel, Protein Damage and Repair in Aging.
    Date: February 25-26, 2008.
    Time: 6 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Hotel, One Metro Center Drive, Bethesda, MD 
20892.
    Contact Person: Elaine Lewis, PhD, Scientific Review 
Administrator, Scientific Review Office, National Institute on 
Aging, Gateway Building, Suite 2C212, MSC-9205, 7201 Wisconsin 
Avenue, Bethesda, MD 20892, 301-402-7707, <a href="/cdn-cgi/l/email-protection#f7929b969e99929b92809e84b7999e96d9999e9fd9909881"><span class="__cf_email__" data-cfemail="72171e131b1c171e17051b01321c1b135c1c1b1a5c151d04">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: January 17, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-312 Filed 1-25-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Ameritas Life Insurance Corp.


 


MINIMUM PREMIUM RIDER


 


This rider is made a part of the policy and is based
on the application and payment of the premium. This rider is subject to the terms and provisions of the policy and this
rider. If there is a conflict between the terms of the policy and the terms of this rider, the rider language controls. This rider
may not be cancelled and will terminate when the policy to which it is attached terminates or the maturity date.


 


Subject to the terms and conditions stated below,
this rider changes the minimum initial premium requirement to the amount shown on your rider schedule. Additional premium
requirements provided in the policy are unaffected by this rider.


 


RIDER CHARGE. Beginning with the policy
date, each month a rider charge will be assessed based on the accumulation value at that time and the charge shown
on your rider schedule. The rider charge will be deducted pro-rata from the fixed account and subaccounts.
When your rider is issued, the current charge applies. After the first policy year, we reserve the right to
change the current charge at any time; however, your charge will never exceed the maximum charge.  If the rider
charge rate increases, we will notify you at least 30 days prior to the policy anniversary.


 


WAIVER OF CHARGES. On each policy anniversary,
we will compare your accumulation value to the waiver threshold stated on your rider schedule. In the event
your accumulation value exceeds the waiver threshold, we will waive charges for this rider. Once waived, the charges
for this rider will be waived for all subsequent policy years.


 


AMERITAS LIFE INSURANCE CORP.


 


 


	[	SPECIMEN	SPECIMEN	]
	   President	Secretary   


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


ICC15 MPR 8-15
EXHIBIT 32.1   CERTIFICATION CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002   Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Propell Corporation  (the Registrant) hereby certifies, to such officers knowledge, that:  (1)the accompanying Amendment No.2 to the Quarterly Report on Form 10-Q/A  of the Registrant for the period ended March 31, 2010 (the Report) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.  Date: March 7, 2011    By:   /s/ Edward L. Bernstein Name: Edward L. Bernstein Title: Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
# Iris Oifigiúil L NaN/2016

| | ISSN 1977-0839 |
| --- | --- |
| Iris Oifigiúil
  an Aontais Eorpaigh | Eagrán Speisialta (
  *1
  ) |
| | |
| An t-eagrán Gaeilge | Reachtaíocht | Imleabhar 5913 Bealtaine 2016 |

ISSN 1977-0839

Iris Oifigiúil

an Aontais Eorpaigh

Eagrán Speisialta (
  *1
  )

*1

An t-eagrán Gaeilge

Reachtaíocht

Imleabhar 5913 Bealtaine 2016

---

| Clár | | II   Gníomhartha neamhreachtacha | Leathanach |
| --- | --- | --- | --- |
| | | COMHAONTUITHE IDIRINSTITIÚIDEACHA |
| | * | Ráiteas ó Pharlaimint na hEorpa agus ón gCoimisiún ar thráth glactha an Chomhaontaithe idirinstitiúidigh maidir le reachtóireacht níos fearr an 13 Aibreán 2016 | 1 |

Clár

II   Gníomhartha neamhreachtacha

Leathanach

COMHAONTUITHE IDIRINSTITIÚIDEACHA

*

Ráiteas ó Pharlaimint na hEorpa agus ón gCoimisiún ar thráth glactha an Chomhaontaithe idirinstitiúidigh maidir le reachtóireacht níos fearr an 13 Aibreán 2016

1

| | |
| --- | --- |
| | (*1)   Faoin tagairt L 124 a foilsíodh ábhar an eagráin seo i dteangacha oifigiúla eile an Aontais Eorpaigh. |

---

(*1)   Faoin tagairt L 124 a foilsíodh ábhar an eagráin seo i dteangacha oifigiúla eile an Aontais Eorpaigh.

*1

| GA | Tagraíonn gníomhartha a bhfuil a dteidil i gcló éadrom do bhainistiú cúrsaí talmhaíochta ó lá go lá agus go ginearálta bíonn tréimhse theoranta bailíochta i gceist leo.
  Tá teidil na ngníomhartha eile i gcló trom agus tagann réiltín rompu. |
| --- | --- |

GA

Tagraíonn gníomhartha a bhfuil a dteidil i gcló éadrom do bhainistiú cúrsaí talmhaíochta ó lá go lá agus go ginearálta bíonn tréimhse theoranta bailíochta i gceist leo.

Tá teidil na ngníomhartha eile i gcló trom agus tagann réiltín rompu.

---

II Gníomhartha neamhreachtacha

COMHAONTUITHE IDIRINSTITIÚIDEACHA

| 13.5.2016 | GA | Iris Oifigiúil an Aontais Eorpaigh | 1 |
| --- | --- | --- | --- |

13.5.2016

GA

Iris Oifigiúil an Aontais Eorpaigh

1

---

RÁITEAS Ó PHARLAIMINT NA hEORPA AGUS ÓN gCOIMISIÚN AR THRÁTH GLACTHA AN CHOMHAONTAITHE IDIRINSTITIÚIDIGH MAIDIR LE REACHTÓIREACHT NÍOS FEARR AN 13 AIBREÁN 2016

Measann Parlaimint na hEorpa agus an Coimisiún gur léiriú é an Comhaontú (1) seo ar an gcothromaíocht idir Parlaimint na hEorpa, an Chomhairle agus an Coimisiún mar a leagtar amach sna Conarthaí í agus gur léiriú é freisin ar inniúlachtaí faoi seach na n-institiúidí sin.

1

Tá sé gan dochar do Chreat-Chomhaontú an 20 Deireadh Fómhair 2010 maidir leis an gcaidreamh idir Parlaimint na hEorpa agus an Coimisiún Eorpach (2).

2

---

(1)  
  IO L 123, 12.5.2016, lch. 1.

1

(2)  
  IO L 304, 20.11.2010, lch. 47.

2

---
<PAGE>

                                                                    EXHIBIT 32.2

I, Keith G. Collin, Chief Financial Officer of Power Efficiency Corporation,
certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that:

1.       the Annual on Form 10-KSB of the Company for the quarter ended December
         31, 2003 (the "Report") fully complies with the requirements of Section
         13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or
         78o(d)); and

2.       the information contained in the Report fairly represents, in all
         material respects, the financial condition and results of operations of
         the Company.

Date:  March 2, 2004

         BY:      /s/ Keith G. Collin
                  --------------------------
                  Keith G. Collin
                  Chief Financial Officer

The foregoing certification is being furnished solely pursuant to section 906 of
the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter
63 of title 18, United States Code) and is not being filed as part of a separate
disclosure document.
Exhibit 32


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Monet Entertainment, Group Ltd. (the
"Company") on Form 10-KSB for the fiscal year ended December 31, 2003 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Stephen Replin, Chief Executive Officer and Chief Financial Officer, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.






March 26, 2004               /s/ Stephen Replin
-------------              ------------------------------
                                 Stephen Replin
                                 Chief Executive Officer
                                 Chief Financial Officer
[Federal Register Volume 73, Number 54 (Wednesday, March 19, 2008)]
[Rules and Regulations]
[Page 14687]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-55505]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1


Income Taxes

CFR Correction

    In Title 26 of the Code of Federal Regulations, Part 1 (Sec.  
1.1551 to End), revised as of April 1, 2007, on page 439, in Sec.  
1.6654-2, in the undesignated paragraph following paragraph 
(d)(2)(ii)(B), make the following changes:
    1. In the first sentence, after the word ``attributable'', insert 
the words ``to months in such partnership taxable''; and
    2. At the beginning of the third sentence, remove the words ``In 
addition, a partner shall include in his taxing after December'' and 
add the words ``In addition, a partner shall include in his taxable 
income and, for taxable years beginning after December'' in their 
place.

[FR Doc. 08-55505 Filed 3-18-08; 8:45 am]
BILLING CODE 1505-01-D
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [FDA No. 225-07-8007]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

      ( print page 6974)    

# SUMMARY:

The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the National Institutes of Health (NIH). This MOU establishes the terms of collaboration between the two Federal agencies to develop a unified Federal approach to adverse event (AE) reporting. Specifically, FDA and NIH will collaborate in development of a project that will result in a web-based method for consumers, health professionals, investigators, sponsors, and other parties to electronically submit AE reports. The project includes the development of at least two products:  (1) A Rational Questionnaire, an interactive help system that will assist reporters of information in determining what specific data need to be submitted and to whom, and (2) a prototype to test the feasibility of a central, Federal web-based portal to provide direct, seamless, online submission of adverse event reports to appropriate agencies.

# DATES:

The agreement became effective September 27, 2007.

# FOR FURTHER INFORMATION CONTACT:

Daryl Allis, OC/Office of Critical Path Programs, Food and Drug Administration, 5600 Fishers Lane (HF-18), Rockville, MD  20785, 301-827-7868.

# SUPPLEMENTARY INFORMATION:

                    In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the                     **Federal Register**                    , the agency is publishing notice of this MOU.                

Dated: January 28, 2008.

Jeffrey Shuren,

Assistant Commissioner for Policy.

      ( print page 6975)          ( print page 6976)          ( print page 6977)          ( print page 6978)          ( print page 6979)          ( print page 6980)          ( print page 6981)          ( print page 6982)    

BILLING CODE 4160-01-S

[FR Doc. 08-496 Filed 2-5-08; 8:45 am]

BILLING CODE 4160-01-C
[Federal Register Volume 73, Number 18 (Monday, January 28, 2008)]
[Notices]
[Page 4881]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-316]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Research Resources; Notice of Closed Meetings

     Pursuant to section 10(d) of the Federal Advisory Committee Act, 
as amended (5 U.S.C. appendix 2), notice is hereby given of the 
following meetings.
     The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Research Resources 
Special Emphasis Panel, SEPA 08 Teleconference.
    Date: February 25, 2008.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, One Democracy Plaza, 6701 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Bonnie Dunn, PhD, Scientific Review Officer, 
Office of Review, National Center for Research Resources, National 
Institutes of Health, 6701 Democracy Blvd., Democracy I, Room 1074, 
MSC 4874, Bethesda, MD 20892-4874, 301-435-0824, 
<a href="/cdn-cgi/l/email-protection#284c5d46464a47684549414406464140064f475e"><span class="__cf_email__" data-cfemail="90f4e5fefef2ffd0fdf1f9fcbefef9f8bef7ffe6">[email protected]</span></a>.

    Name of Committee: National Center for Research Resources 
Special Emphasis Panel, Research on Research Integrity.
    Date: March 18, 2008.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Washington/Rockville, DoubleTree name changed, 
1750 Rockville Pike, Rockville, MD 20852.
    Contact Person: Bonnie Dunn, PhD, Scientific Review Officer, 
Office of Review, National Center for Research Resources, National 
Institutes of Health, 6701 Democracy Blvd., 1 Democracy Blvd., Rm. 
1074, Bethesda, MD 20892-4874, (301) 435-0824, <a href="/cdn-cgi/l/email-protection#92f6e7fcfcf0fdd2fff3fbfebcfcfbfabcf5fde4"><span class="__cf_email__" data-cfemail="1f7b6a71717d705f727e76733171767731787069">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical 
Technology; 93.389, Research Infrastructure, National Institutes of 
Health, HHS)

    Dated: January 17, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-316 Filed 1-25-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
115TH CONGRESS 

2D SESSION H. R. 6029 

AN ACT 

To amend the Omnibus Crime Control and Safe Streets 

Act of 1968 to reauthorize the comprehensive opioid 

abuse grant program, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 6029 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Reauthorizing and Ex3 tending Grants for Recovery from Opioid Use Programs 

4 Act of 2018’’ or the ‘‘REGROUP Act of 2018’’. 

5 SEC. 2. REAUTHORIZATION OF THE COMPREHENSIVE 

6 OPIOID ABUSE GRANT PROGRAM. 

7 Section 1001(a)(27) of the Omnibus Crime Control 

8 and Safe Streets Act of 1968 (34 U.S.C. 10261(a)(27)) 

9 is amended by striking ‘‘through 2021’’ and inserting 

10 ‘‘and 2018, and $330,000,000 for each of fiscal years 

11 2019 through 2023’’. 

Passed the House of Representatives June 13, 2018. 

Attest: 

Clerk. 

115TH CONGRESS 

2D SESSION H. R. 6029 

AN ACT 

To amend the Omnibus Crime Control and Safe 

other purposes. prehensive opioid abuse grant program, and for Streets Act of 1968 to reauthorize the com-
Exhibit
32.1





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





I, Ronald
Williams, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report
on Form 10-Q of DRC Ventures, Inc. for the quarter ended December 31, 2010
fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934 and that information contained in such
Quarterly Report on Form 10-Q fairly presents in all material respects the
financial condition and results of operations of DRC Ventures, Inc.





Dated:
      February 11, 2011
            By:
            /s/ Ronald WilliamsName:
            Ronald
      WilliamsTitle:
            President,
      Principal Executive Officer
              and
      Principal Financial Officer





The
foregoing certification is being furnished solely pursuant to 18 U.S.C. Section
1350 and is not being filed as part of the Report or as a separate disclosure
document.
CERTIFICATIONS  I, Jay Lutsky, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tiger Acquisitions, Inc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: (a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)         designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements, for external purposes in accordance with generally accepted accounting principles; (c)         evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)         Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a)         all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial information; and b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  Date: August 19, 2008 /s/ Jay LutskyJay Lutsky, Chief Financial Officer
### T E X A S C O U R T O F A P P E A L S , T H I R D D I S T R I C T , A T A U S T I N NO. 03-09-00586- CR Michael Anthony Polizz i, Appellan t

v. The State of Texas, App ellee F ROM TH E DISTRI CT COURT O F B ELL COUNTY , 264 TH JUDICI AL DISTRICT NO. 646 97, H ONO RAB LE MARTH A J. TRUDO , JUDGE P RESIDING

M E M O R A N D U M O P I N I O N Appellant’s motion to dismi ss this appeal is g rante d. SeeTex. R. App. P . 42.2(a) . The a ppeal is dismissed.

__________________________________________ J . Woodfin J ones, Chief Just ice Be fore Chief J ustice Jones, J ustices Pemberton a nd Waldrop Dismissed on Appellant’s Motion Filed: January

29, 2010 Do Not Publish